Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 6/20 | 0.51 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NCF1 | P14598 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | FLT1 | P17948 | 1/20 | 0.30 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.30 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.30 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.30 |
| ▸ | FLT4 | P35916 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5046229 | 1.00 | ERBB2 (0.51) | ERBB2MINK1PDGFRBAPPMAPT | |
| SCHEMBL5046482 | 0.92 | ERBB2 (0.52) | ERBB2MINK1NCF1 | |
| SCHEMBL5046476 | 0.92 | ERBB2 (0.52) | ERBB2MINK1NCF1 | |
| SCHEMBL5047849 | 0.90 | ERBB2 (0.52) | ERBB2MINK1NCF1 | |
| SCHEMBL5047856 | 0.90 | ERBB2 (0.52) | ERBB2MINK1NCF1 | |
| SCHEMBL5046169 | 0.90 | ERBB2 (0.54) | ERBB2MINK1PDGFRBAPPMAPT | |
| SCHEMBL5046167 | 0.90 | ERBB2 (0.54) | ERBB2MINK1PDGFRBAPPMAPT | |
| SCHEMBL5046148 | 0.88 | ERBB2 (0.52) | ERBB2MINK1APPMAPT | |
| SCHEMBL5046146 | 0.88 | ERBB2 (0.52) | ERBB2MINK1APPMAPT | |
| SCHEMBL5043332 | 0.86 | ERBB2 (0.62) | ERBB2MINK1NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432291-B2 | Ether derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-10-07 | — | — | US | claimed |
| EP-1727815-B1 | ETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2007-06-27 | — | — | EP | claimed |
| EP-1727815-A1 | ETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-12-06 | — | — | EP | claimed |
| WO-2005090338-A1 | ETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-29 | — | — | WO | claimed |
| US-20050209290-A1 | Novel ether derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2005-09-22 | — | — | US | claimed |
| US-7432291-B2 | Ether derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1727815-B1 | ETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2007-06-27 | — | — | EP | disclosed |
| EP-1727815-A1 | ETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005090338-A1 | ETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-29 | — | — | WO | disclosed |
| US-20050209290-A1 | Novel ether derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209290-A1 | Novel ether derivatives | CYP2E1, CYP11B1, CYP11B2 | ERBB2 823/4885MINK1 2620/4885PDGFRB 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.